MapLight Therapeutics Secures $150M Private Placement and Reports Q2 Results
MPLT sits 29% above its 52-week low of $9.1.
Summary
MapLight Therapeutics announced a $150 million private placement of common stock and pre-funded warrants, extending its cash runway through 2028. The company also reported Q2 2026 financial results and provided an updated corporate presentation.
Key Events · Financing and Capital Events · MPLT
-
$150M Private Placement
A securities purchase agreement was entered into by MapLight to sell 9,197,887 shares of common stock at $11.38 per share and pre-funded warrants to purchase 3,983,168 shares at $11.3799 per warrant, for gross proceeds of approximately $150 million.
-
Pre-Funded Warrants
The pre-funded warrants have an exercise price of $0.0001 per share, are immediately exercisable, and do not expire. They are economically equivalent to common stock and were issued in lieu of shares to certain investors.
-
Registration Rights
The company agreed to file a resale registration statement within 30 days of closing. If the registration statement is not filed or declared effective on time, the company will pay liquidated damages of 1.0% of the purchase price per 30-day period, capped at 5.0%.
-
Q2 2026 Financial Results
MapLight reported a net loss of $60.2 million for Q2 2026, with R&D expenses of $53.4 million and G&A expenses of $10.1 million. Cash, cash equivalents and investments totaled $351.3 million as of June 30, 2026.
Analysis · MPLT · Life Sciences
A $150 million private placement has been secured by MapLight Therapeutics through a securities purchase agreement, involving the sale of 9.2 million shares at $11.38 each and pre-funded warrants for 4.0 million shares at $11.3799 per warrant. The financing extends the company's cash runway through 2028 and supports the Phase 3 ZEPHYR-2 trial for ML-007C-MA in schizophrenia. Q2 2026 results were also reported, showing a net loss of $60.2 million and cash of $351.3 million. The placement is priced at a slight discount to the current stock price of $11.70, and the pre-funded warrants carry a nominal exercise price of $0.0001, making them economically equivalent to common stock. Under the registration rights agreement, resale registration is required within 30 days, with liquidated damages applying for delays.
At the time of this filing, MPLT was trading at $11.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.5M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.